February 9, 2017 / 9:25 PM / 8 months ago

BRIEF-Aveo reports clinical and regulatory updates for tivozanib

Feb 10 (Reuters) - Aveo Pharmaceuticals Inc :

* Aveo announces clinical and regulatory updates for tivozanib

* Aveo Pharmaceuticals Inc- phase 1/2 tinivo trial sites scheduled to open for enrollment in early march

* Aveo Pharmaceuticals Inc- partner Eusa Pharma receives day 180 list of outstanding issues from EMA, oral explanation expected in 2q 2017

* Aveo Pharmaceuticals Inc- pivotal tivo-3 trial enrollment proceeding substantially ahead of schedule; enrollment completion expected in June

* Aveo Pharmaceuticals Inc- initial results from opdivo(reg) combination tinivo study expected in RCC in first half of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below